NASDAQ:LAB Standard BioTools (LAB) Stock Price, News & Analysis $1.03 -0.01 (-0.96%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Standard BioTools Stock (NASDAQ:LAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Standard BioTools alerts:Sign Up Key Stats Today's Range$1.02▼$1.0650-Day Range$0.88▼$1.0652-Week Range$0.87▼$1.72Volume1.15 million shsAverage Volume2.15 million shsMarket Capitalization$402.08 millionP/E Ratio5.15Dividend YieldN/APrice Target$1.35Consensus RatingReduce Company Overview Standard BioTools, Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide. The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling. Standard BioTools also offers real-time PCR arrays, microfluidic access arrays and reagents designed to streamline workflows for target validation, drug discovery and translational research. Headquartered in South San Francisco, Standard BioTools maintains sales and support operations across North America, Europe and Asia, serving a global customer base of life science researchers and clinicians. The company invests in application development and cross-platform software that enables users to integrate proteomic, genomic and imaging data for deeper biological insights. In October 2023, the company rebranded from Fluidigm to Standard BioTools to reflect its unified approach to multi-omic and spatial biology solutions. Led by an experienced management team with backgrounds in life sciences innovation and instrumentation, Standard BioTools continues to expand its product portfolio and market reach. AI Generated. May Contain Errors. Read More Standard BioTools Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreLAB MarketRank™: Standard BioTools scored higher than 61% of companies evaluated by MarketBeat, and ranked 593rd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingStandard BioTools has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialStandard BioTools has a consensus price target of $1.35, representing about 30.4% upside from its current price of $1.04.Amount of Analyst CoverageStandard BioTools has only been the subject of 1 research reports in the past 90 days.Read more about Standard BioTools' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Standard BioTools is 5.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Standard BioTools is 5.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.06.Price to Book Value per Share RatioStandard BioTools has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Standard BioTools' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.94% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 4.25.Change versus previous monthShort interest in Standard BioTools has recently increased by 39.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStandard BioTools does not currently pay a dividend.Dividend GrowthStandard BioTools does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentStandard BioTools has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Standard BioTools this week, compared to 2 articles on an average week.Search Interest6 people have searched for LAB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Standard BioTools insiders have not sold or bought any company stock.Percentage Held by Insiders23.16% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Standard BioTools' insider trading history. Receive LAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LAB Stock News HeadlinesCasdin funds buys Standard Biotools (LAB) shares worth $443,032May 21 at 12:57 PM | investing.comStandard BioTools Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.May 22 at 1:00 AM | Porter & Company (Ad)Standard BioTools Receives Nasdaq Minimum Bid Price Deficiency NoticeApril 24, 2026 | tipranks.comStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026April 22, 2026 | finance.yahoo.comStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 24, 2026 | globenewswire.comStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026February 10, 2026 | globenewswire.comStandard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth StrategyJanuary 30, 2026 | quiverquant.comQSee More Headlines LAB Stock Analysis - Frequently Asked Questions How have LAB shares performed this year? Standard BioTools' stock was trading at $1.28 at the start of the year. Since then, LAB shares have decreased by 19.1% and is now trading at $1.0350. How were Standard BioTools' earnings last quarter? Standard BioTools Inc. (NASDAQ:LAB) issued its earnings results on Tuesday, February, 24th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.08. The company had revenue of $23.80 million for the quarter, compared to analysts' expectations of $18.50 million. Standard BioTools had a negative trailing twelve-month return on equity of 8.18% and a net margin of 73.46%. When did Standard BioTools IPO? Standard BioTools (LAB) raised $75 million in an IPO on Thursday, February 10th 2011. The company issued 5,172,414 shares at a price of $13.50-$15.50 per share. Who are Standard BioTools' major shareholders? Standard BioTools' top institutional shareholders include Bank of New York Mellon Corp (0.20%), Staley Capital Advisers Inc. (0.16%), Amova Asset Management Americas Inc. (0.11%) and Sumitomo Mitsui Trust Group Inc. (0.11%). Insiders that own company stock include Casdin Partners Master Fund, L, Michael Egholm, Hanjoon Alex Kim and Sean Mackay. View institutional ownership trends. How do I buy shares of Standard BioTools? Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Standard BioTools own? Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings2/24/2026Today5/22/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LAB's financial health is in the Yellow zone, according to TradeSmith. LAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:LAB Previous SymbolNASDAQ:SLGC CIK1162194 Webwww.fluidigm.com Phone(650) 266-6000Fax650-871-7152Employees620Year Founded1999Price Target and Rating Average Price Target for Standard BioTools$1.35 High Price Target$1.35 Low Price Target$1.35 Potential Upside/Downside+31.1%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.20 Trailing P/E Ratio5.15 Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.90 million Net Margins73.46% Pretax Margin-82.50% Return on Equity-8.18% Return on Assets-6.43% Debt Debt-to-Equity RatioN/A Current Ratio12.36 Quick Ratio11.92 Sales & Book Value Annual Sales$86.26 million Price / Sales4.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book0.72Miscellaneous Outstanding Shares390,368,000Free Float299,959,000Market Cap$402.08 million OptionableOptionable Beta1.32 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:LAB) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne coin wired into Elon's visionSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
